BRPI0812889A2 - composto, composição farmacêutica, uso de um composto, e, método para o tratamento ou prevenção de distúrbios neurológicos e psiquiátricos associados com a disfunção de glutamato em um animal. - Google Patents

composto, composição farmacêutica, uso de um composto, e, método para o tratamento ou prevenção de distúrbios neurológicos e psiquiátricos associados com a disfunção de glutamato em um animal.

Info

Publication number: BRPI0812889A2
Authority: BR; Brazil
Prior art keywords: compound; neurological; animal; prevention; treatment
Prior art date: 2007-06-07

Application number

BRPI0812889A

Other languages

English (en)

Inventor

Slassi Abdelmalik

Ma Fupeng

Empfield James

Folmer James

Clayton Joshua

Egle Lan

Isaac Methvin

Original Assignee

Astrazeneca Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-06-07

Filing date

2008-06-05

Publication date

2017-05-23

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40093925&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0812889(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2008-06-05 Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab

2017-05-23 Publication of BRPI0812889A2 publication Critical patent/BRPI0812889A2/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Physical Education & Sports Medicine (AREA)
Addiction (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Orthopedic Medicine & Surgery (AREA)
Urology & Nephrology (AREA)
Psychology (AREA)
Diabetes (AREA)
Anesthesiology (AREA)
Ophthalmology & Optometry (AREA)
Hospice & Palliative Care (AREA)
Rheumatology (AREA)
Hematology (AREA)
Vascular Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Epidemiology (AREA)

BRPI0812889A 2007-06-07 2008-06-05 composto, composição farmacêutica, uso de um composto, e, método para o tratamento ou prevenção de distúrbios neurológicos e psiquiátricos associados com a disfunção de glutamato em um animal. BRPI0812889A2 (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US94255307P	2007-06-07	2007-06-07
PCT/SE2008/050666 WO2008150233A1 (en)	2007-06-07	2008-06-05	Oxadiazole derivatives and their use as metabotropic glutamate receptor potentiators - 842

Publications (1)

Publication Number	Publication Date
BRPI0812889A2 true BRPI0812889A2 (pt)	2017-05-23

Family

ID=40093925

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0812889A BRPI0812889A2 (pt)	2007-06-07	2008-06-05	composto, composição farmacêutica, uso de um composto, e, método para o tratamento ou prevenção de distúrbios neurológicos e psiquiátricos associados com a disfunção de glutamato em um animal.

Country Status (33)

Country	Link
US (2)	US8377940B2 (pt)
EP (2)	EP2167502B3 (pt)
JP (2)	JP5416696B2 (pt)
KR (2)	KR20100017640A (pt)
CN (2)	CN102977086B (pt)
AR (1)	AR066882A1 (pt)
AU (1)	AU2008260717B2 (pt)
BR (1)	BRPI0812889A2 (pt)
CA (1)	CA2690856C (pt)
CL (1)	CL2008001667A1 (pt)
CO (1)	CO6251287A2 (pt)
CY (2)	CY1113422T1 (pt)
DK (2)	DK2444399T3 (pt)
EC (1)	ECSP109856A (pt)
ES (2)	ES2393425T7 (pt)
HR (2)	HRP20120909T4 (pt)
IL (1)	IL202158A (pt)
ME (1)	ME01488B (pt)
MX (1)	MX2009013078A (pt)
MY (1)	MY158066A (pt)
NZ (1)	NZ582445A (pt)
PE (1)	PE20090328A1 (pt)
PL (2)	PL2444399T3 (pt)
PT (2)	PT2444399E (pt)
RS (2)	RS53845B1 (pt)
RU (2)	RU2470931C2 (pt)
SA (1)	SA08290344B1 (pt)
SI (2)	SI2444399T1 (pt)
TW (1)	TWI417100B (pt)
UA (1)	UA99129C2 (pt)
UY (1)	UY31124A1 (pt)
WO (1)	WO2008150233A1 (pt)
ZA (1)	ZA200908285B (pt)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7807706B2 (en) *	2005-08-12	2010-10-05	Astrazeneca Ab	Metabotropic glutamate-receptor-potentiating isoindolones
US7868008B2 (en) *	2005-08-12	2011-01-11	Astrazeneca Ab	Substituted isoindolones and their use as metabotropic glutamate receptor potentiators
TW200804281A (en) *	2006-02-16	2008-01-16	Astrazeneca Ab	New metabotropic glutamate receptor-potentiating isoindolones
TWI417095B (zh)	2006-03-15	2013-12-01	Janssen Pharmaceuticals Inc	１，４-二取代之３-氰基-吡啶酮衍生物及其作為ｍＧｌｕＲ２-受體之正向異位性調節劑之用途
TW200900065A (en)	2007-03-07	2009-01-01	Janssen Pharmaceutica Nv	3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
TW200845978A (en)	2007-03-07	2008-12-01	Janssen Pharmaceutica Nv	3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
TW200911255A (en)	2007-06-07	2009-03-16	Astrazeneca Ab	Metabotropic glutamate receptor oxadiazole ligands and their use as potentiators-841
TWI417100B (zh) *	2007-06-07	2013-12-01	Astrazeneca Ab	二唑衍生物及其作為代謝型麩胺酸受體增效劑-８４２之用途
MY152078A (en)	2007-09-14	2014-08-15	Ortho Mcneil Janssen Pharm	1',3'-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2h,1'h-[1,4']bipyridinyl-2'-ones
CA2697399C (en)	2007-09-14	2016-01-19	Ortho-Mcneil-Janssen Pharmaceuticals, Inc.	1,3-disubstituted 4-(aryl-x-phenyl)-1h-pyridin-2-ones
NZ584148A (en)	2007-09-14	2011-05-27	Ortho Mcneil Janssen Pharm	1,3-disubstituted-4-phenyl-1 h-pyridin-2-ones
RU2492170C9 (ru) *	2007-11-14	2013-12-27	Орто-Макнейл-Янссен Фармасьютикалз, Инк.	Имидазо[1,2-а]пиридиновые производные и их применение в качестве положительных аллостерических модуляторов рецепторов mglur2
SA109300358B1 (ar) *	2008-06-06	2012-11-03	استرازينيكا ايه بي	مقويات مستقبل جلوتامات ذي انتحاء أيضي من أيزو إندولون
MY157518A (en)	2008-06-20	2016-06-15	Astrazeneca Ab	Dibenzothiazepine derivatives and use thereof
AU2009289784B2 (en)	2008-09-02	2012-03-22	Addex Pharma S.A.	3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors
ES2466341T3 (es)	2008-10-16	2014-06-10	Janssen Pharmaceuticals, Inc.	Derivados de indol y benzomorfolina como moduladores de receptores de glutamato metabotrópicos
WO2010060589A1 (en)	2008-11-28	2010-06-03	Ortho-Mcneil-Janssen Pharmaceuticals, Inc.	Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors
AU2010246609B2 (en)	2009-05-12	2013-09-05	Addex Pharma S.A.	1,2,4-triazolo [4,3-a] pyridine derivatives and their use for the treatment or prevention of neurological and psychiatric disorders
NZ596053A (en)	2009-05-12	2013-05-31	Janssen Pharmaceuticals Inc	1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
MY153913A (en)	2009-05-12	2015-04-15	Janssen Pharmaceuticals Inc	7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
MX2012007992A (es) *	2010-01-07	2012-08-03	Astrazeneca Ab	Proceso para producir modulador alosterico positivo receptor de glutamato metabotropico - 874.
CA2795218A1 (en) *	2010-04-30	2011-11-03	Helen Blade	Polymorphs of a metabotropic glutamate receptor positive allosteric modulator
CN103298810B (zh)	2010-11-08	2016-03-16	杨森制药公司	1,2,4-三唑并[4,3-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途
EP2643320B1 (en)	2010-11-08	2015-03-04	Janssen Pharmaceuticals, Inc.	1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
EP2661435B1 (en)	2010-11-08	2015-08-19	Janssen Pharmaceuticals, Inc.	1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
CN102180872B (zh) *	2011-04-01	2014-04-02	华中科技大学	[1,3,4]噁二唑类衍生物及其应用
JO3368B1 (ar)	2013-06-04	2019-03-13	Janssen Pharmaceutica Nv	مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar)	2013-09-06	2019-03-13	Janssen Pharmaceutica Nv	مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
DK3096790T3 (da)	2014-01-21	2019-10-07	Janssen Pharmaceutica Nv	Kombinationer omfattende positive allosteriske modulatorer eller orthosteriske agonister af metabotrop glutamaterg subtype 2-receptor og anvendelse af disse
KR20220038826A (ko)	2014-01-21	2022-03-29	얀센 파마슈티카 엔.브이.	대사 조절형 글루탐산 작동성 수용체 제2아형의 양성 알로스테릭 조절제 또는 오르토스테릭 작동제를 포함하는 조합 및 그 용도
EP3325475B1 (en)	2015-07-17	2020-03-18	Takeda Pharmaceutical Company Limited	Oxadiazole derivatives useful as hdac inhibitors
WO2017014170A1 (ja) *	2015-07-17	2017-01-26	武田薬品工業株式会社	複素環化合物
EP3342772A4 (en)	2015-08-25	2019-03-27	Takeda Pharmaceutical Company Limited	HETEROCYCLIC COMPOUND
WO2020102198A1 (en)	2018-11-13	2020-05-22	Incyte Corporation	Heterocyclic derivatives as pi3k inhibitors
US11396502B2 (en)	2018-11-13	2022-07-26	Incyte Corporation	Substituted heterocyclic derivatives as PI3K inhibitors
US11161838B2 (en)	2018-11-13	2021-11-02	Incyte Corporation	Heterocyclic derivatives as PI3K inhibitors
US20220273572A1 (en) *	2019-07-18	2022-09-01	Abaxys Therapeutics	Solid formulation of a 1,2,4-oxadiazole derivative
GB2621323A (en) *	2022-08-03	2024-02-14	Sirgartan Holdings Ltd	Treatments for obsessive compulsive disorder

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2008803A (en) *	1932-04-18	1935-07-23	Stephan Engineering Corp	Fuel atomizing and igniting means
US3993617A (en) *	1975-10-30	1976-11-23	Morton-Norwich Products, Inc.	Antifungal 2-substituted phthalimidines
US5175157A (en) *	1985-11-27	1992-12-29	Boehringer Ingelheim Gmbh	Cyclic amine derivatives, pharmaceutical compositions containing these compounds and methods for preparing them
WO1992017448A1 (fr)	1991-04-01	1992-10-15	Kyowa Hakko Kogyo Co., Ltd.	Derive de 3-methylenisoindolin-1-one
TW219935B (pt)	1991-12-25	1994-02-01	Mitsubishi Chemicals Co Ltd
EP0602814A1 (en)	1992-12-18	1994-06-22	Takeda Chemical Industries, Ltd.	Crystal forms of optically active isoindolines and their use
RU2124511C1 (ru) *	1993-05-14	1999-01-10	Фармасьютикал Ко., Лтд	Производные пиперазина
US5681954A (en) *	1993-05-14	1997-10-28	Daiichi Pharmaceutical Co., Ltd.	Piperazine derivatives
CA2245586A1 (en) *	1996-02-06	1997-08-14	Japan Tobacco Inc.	Novel compounds and pharmaceutical use thereof
WO1998054135A1 (en)	1997-05-30	1998-12-03	Meiji Seika Kaisha, Ltd.	Nitrogenous heterocyclic compounds and hyperlipemia remedy containing the same
NZ505207A (en)	1997-11-21	2003-10-31	Nps Pharma Inc	Metabotropic glutamate receptor antagonists for treating central nervous system diseases
DK1260512T3 (da) *	2000-02-29	2007-11-05	Mitsubishi Pharma Corp	Hidtil ukendte, cykliske amidderivater
KR20030059084A (ko)	2000-07-31	2003-07-07	스미스크라인 비참 피.엘.시.	카르복사미드 화합물 및 이것의 사람 11ｃｂｙ 수용체의길항제로서의 용도
CA2446924C (en) *	2001-04-19	2011-02-08	Eisai Co., Ltd.	2-iminopyrrolidine derivatives
MXPA04001253A (es)	2001-08-09	2004-06-03	Ono Pharmaceutical Co	Derivados de acidos carboxilicos y agente farmaceutico que comprende los mismos como ingrediente activo.
AU2003226927A1 (en)	2002-04-09	2003-10-27	7Tm Pharma A/S	Novel carboxamide compounds for use in mch receptor related disorders
FR2840302B1 (fr)	2002-06-03	2004-07-16	Aventis Pharma Sa	Derives d'isoindolones, procede de preparation et intermediaire de ce procede a titre de medicaments et compositions pharmaceutiques les renfermant
DE10238865A1 (de)	2002-08-24	2004-03-11	Boehringer Ingelheim International Gmbh	Neue Carbonsäureamid-Verbindungen mit MCH-antagonistischer Wirkung, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
GB0223232D0 (en)	2002-10-07	2002-11-13	Pfizer Ltd	Chemical compounds
AU2003284669B2 (en) *	2002-11-26	2009-11-12	Maruishi Pharmaceutical Co., Ltd.	Isoindoline derivative
JP2006521358A (ja)	2003-03-26	2006-09-21	メルク　エンド　カムパニー　インコーポレーテッド	代謝調節型グルタミン酸受容体のベンズアミドモジュレータ
GB0308025D0 (en)	2003-04-07	2003-05-14	Glaxo Group Ltd	Compounds
US7129260B2 (en) *	2003-06-02	2006-10-31	Abbott Laboratories	Isoindolinone kinase inhibitors
EP1723126A2 (en)	2003-10-22	2006-11-22	Eli Lilly And Company	Novel mch receptor antagonists
JP2007519754A (ja)	2004-01-30	2007-07-19	スミスクラインビーチャムコーポレーション	化合物
MY152888A (en) *	2004-02-18	2014-11-28	Astrazeneca Ab	Fused heterocyclic compounds and their use as metabotropic glutamate receptor antagonists.
US7902369B2 (en)	2004-03-05	2011-03-08	Banyu Pharmaceutical Co., Ltd.	Diaryl-substituted five-membered heterocycle derivative
SI1731512T1 (sl)	2004-03-05	2015-01-30	Nissan Chemical Industries, Ltd.	Z izoksazolinom substituirana benzamidna spojina in sredstvo za uravnavanje Ĺˇkodljivih organizmov
SE0400970D0 (sv)	2004-04-14	2004-04-14	Astrazeneca Ab	Nicotinic acetylcholine receptor ligands
TW200613272A (en) *	2004-08-13	2006-05-01	Astrazeneca Ab	Isoindolone compounds and their use as metabotropic glutamate receptor potentiators
CA2584598A1 (en)	2004-10-25	2006-05-04	Merck & Co., Inc.	Heterocyclic indanone potentiators of metabotropic glutamate receptors
WO2006091496A2 (en)	2005-02-24	2006-08-31	Merck & Co., Inc.	Benzazole potentiators of metabotropic glutamate receptors
NZ564254A (en) *	2005-05-18	2011-04-29	Addex Pharma Sa	Substituted oxadiazole derivatives as positive allosteric modulators of metabotropic glutamate receptors
GB0510142D0 (en) *	2005-05-18	2005-06-22	Addex Pharmaceuticals Sa	Novel compounds A1
TW200728277A (en)	2005-06-29	2007-08-01	Palau Pharma Sa	Bicyclic derivatives as P38 inhibitors
US7868008B2 (en) *	2005-08-12	2011-01-11	Astrazeneca Ab	Substituted isoindolones and their use as metabotropic glutamate receptor potentiators
CN101309905A (zh) *	2005-08-12	2008-11-19	阿斯利康(瑞典)有限公司	取代的异吲哚酮及其作为代谢型谷氨酸受体增效剂的用途
US7807706B2 (en) *	2005-08-12	2010-10-05	Astrazeneca Ab	Metabotropic glutamate-receptor-potentiating isoindolones
JP5048675B2 (ja)	2005-09-27	2012-10-17	エフ．ホフマン−ラロシュアーゲー	ｍＧｌｕＲ２アンタゴニストとしてのオキサジアゾリルピラゾロ−ピリミジン類
TW200804281A (en) *	2006-02-16	2008-01-16	Astrazeneca Ab	New metabotropic glutamate receptor-potentiating isoindolones
TWI417100B (zh) *	2007-06-07	2013-12-01	Astrazeneca Ab	二唑衍生物及其作為代謝型麩胺酸受體增效劑-８４２之用途
TW200911255A (en) *	2007-06-07	2009-03-16	Astrazeneca Ab	Metabotropic glutamate receptor oxadiazole ligands and their use as potentiators-841

2008
- 2008-06-04 TW TW097120762A patent/TWI417100B/zh not_active IP Right Cessation
- 2008-06-05 CN CN201210486921.4A patent/CN102977086B/zh not_active Expired - Fee Related
- 2008-06-05 ES ES08779348T patent/ES2393425T7/es active Active
- 2008-06-05 US US12/663,371 patent/US8377940B2/en not_active Expired - Fee Related
- 2008-06-05 SI SI200831385T patent/SI2444399T1/sl unknown
- 2008-06-05 CA CA2690856A patent/CA2690856C/en not_active Expired - Fee Related
- 2008-06-05 MX MX2009013078A patent/MX2009013078A/es active IP Right Grant
- 2008-06-05 RU RU2009147708/04A patent/RU2470931C2/ru not_active IP Right Cessation
- 2008-06-05 MY MYPI20095187A patent/MY158066A/en unknown
- 2008-06-05 ME MEP-2012-131A patent/ME01488B/me unknown
- 2008-06-05 EP EP08779348.5A patent/EP2167502B3/en active Active
- 2008-06-05 JP JP2010511147A patent/JP5416696B2/ja not_active Expired - Fee Related
- 2008-06-05 PL PL11195016T patent/PL2444399T3/pl unknown
- 2008-06-05 ES ES11195016.8T patent/ES2531443T3/es active Active
- 2008-06-05 CN CN2008800191548A patent/CN101679403B/zh not_active Expired - Fee Related
- 2008-06-05 KR KR1020097025404A patent/KR20100017640A/ko not_active Ceased
- 2008-06-05 AU AU2008260717A patent/AU2008260717B2/en not_active Ceased
- 2008-06-05 KR KR1020157026785A patent/KR20150116907A/ko not_active Ceased
- 2008-06-05 UA UAA200911794A patent/UA99129C2/ru unknown
- 2008-06-05 PL PL08779348T patent/PL2167502T6/pl unknown
- 2008-06-05 BR BRPI0812889A patent/BRPI0812889A2/pt not_active IP Right Cessation
- 2008-06-05 RS RS20150130A patent/RS53845B1/sr unknown
- 2008-06-05 PT PT11195016T patent/PT2444399E/pt unknown
- 2008-06-05 WO PCT/SE2008/050666 patent/WO2008150233A1/en not_active Ceased
- 2008-06-05 NZ NZ582445A patent/NZ582445A/en not_active IP Right Cessation
- 2008-06-05 PT PT08779348T patent/PT2167502E/pt unknown
- 2008-06-05 DK DK11195016T patent/DK2444399T3/en active
- 2008-06-05 AR ARP080102401A patent/AR066882A1/es unknown
- 2008-06-05 HR HRP20120909AT patent/HRP20120909T4/hr unknown
- 2008-06-05 EP EP11195016.8A patent/EP2444399B1/en active Active
- 2008-06-05 RS RS20120507A patent/RS52526B2/sr unknown
- 2008-06-05 DK DK08779348.5T patent/DK2167502T3/da active
- 2008-06-05 SI SI200830807T patent/SI2167502T1/sl unknown
- 2008-06-06 UY UY31124A patent/UY31124A1/es not_active Application Discontinuation
- 2008-06-06 CL CL2008001667A patent/CL2008001667A1/es unknown
- 2008-06-06 US US12/134,553 patent/US8377939B2/en not_active Expired - Fee Related
- 2008-06-06 PE PE2008000965A patent/PE20090328A1/es not_active Application Discontinuation
- 2008-06-07 SA SA08290344A patent/SA08290344B1/ar unknown
2009
- 2009-11-16 IL IL202158A patent/IL202158A/en not_active IP Right Cessation
- 2009-11-23 ZA ZA200908285A patent/ZA200908285B/xx unknown
- 2009-12-04 CO CO09139153A patent/CO6251287A2/es not_active Application Discontinuation
2010
- 2010-01-06 EC EC2010009856A patent/ECSP109856A/es unknown
2012
- 2012-09-25 RU RU2012141706/04A patent/RU2012141706A/ru not_active Application Discontinuation
- 2012-11-22 CY CY20121101132T patent/CY1113422T1/el unknown
2013
- 2013-11-14 JP JP2013235538A patent/JP5815644B2/ja not_active Expired - Fee Related
2015
- 2015-02-24 HR HRP20150210TT patent/HRP20150210T1/hr unknown
- 2015-02-26 CY CY20151100204T patent/CY1116150T1/el unknown

Also Published As

Publication number	Publication date
JP5815644B2 (ja)	2015-11-17
CN101679403A (zh)	2010-03-24
US8377940B2 (en)	2013-02-19
EP2444399A1 (en)	2012-04-25
EP2167502B3 (en)	2013-07-10
US20080306077A1 (en)	2008-12-11
HK1142318A1 (en)	2010-12-03
CY1116150T1 (el)	2017-02-08
RS53845B1 (sr)	2015-08-31
RU2009147708A (ru)	2011-07-20
RU2012141706A (ru)	2014-03-27
CN102977086A (zh)	2013-03-20
ES2393425T7 (es)	2013-11-22
AU2008260717B2 (en)	2012-01-19
JP2010529118A (ja)	2010-08-26
US8377939B2 (en)	2013-02-19
HRP20120909T4 (hr)	2013-11-08
TW200911254A (en)	2009-03-16
RU2470931C2 (ru)	2012-12-27
PL2444399T3 (pl)	2015-04-30
ES2393425T3 (es)	2012-12-21
PT2444399E (pt)	2015-03-04
AR066882A1 (es)	2009-09-16
EP2167502A4 (en)	2011-04-06
ECSP109856A (es)	2010-02-26
EP2444399B1 (en)	2014-11-26
SI2444399T1 (sl)	2015-03-31
PL2167502T3 (pl)	2013-01-31
EP2167502A1 (en)	2010-03-31
DK2167502T3 (da)	2012-12-03
CL2008001667A1 (es)	2009-03-06
MY158066A (en)	2016-08-30
CN102977086B (zh)	2015-04-01
NZ582445A (en)	2012-03-30
ES2531443T3 (es)	2015-03-16
UY31124A1 (es)	2009-01-30
JP2014055164A (ja)	2014-03-27
RS52526B (sr)	2013-04-30
WO2008150233A1 (en)	2008-12-11
JP5416696B2 (ja)	2014-02-12
TWI417100B (zh)	2013-12-01
US20100267740A1 (en)	2010-10-21
KR20150116907A (ko)	2015-10-16
KR20100017640A (ko)	2010-02-16
EP2167502B1 (en)	2012-09-19
ZA200908285B (en)	2010-08-25
CY1113422T1 (el)	2016-06-22
IL202158A0 (en)	2010-06-16
PT2167502E (pt)	2012-11-26
CA2690856C (en)	2015-12-15
HK1166978A1 (en)	2012-11-16
MX2009013078A (es)	2010-01-15
UA99129C2 (ru)	2012-07-25
CO6251287A2 (es)	2011-02-21
HRP20120909T1 (en)	2012-12-31
ME01488B (me)	2014-04-20
PE20090328A1 (es)	2009-04-24
PL2167502T6 (pl)	2013-12-31
IL202158A (en)	2015-11-30
CN101679403B (zh)	2013-01-02
CA2690856A1 (en)	2008-12-11
DK2444399T3 (en)	2015-03-02
HRP20150210T1 (en)	2015-06-05
SI2167502T1 (sl)	2012-12-31
AU2008260717A1 (en)	2008-12-11
RS52526B2 (sr)	2018-06-29
SA08290344B1 (ar)	2011-10-03

Publication	Publication Date	Title
BRPI0812889A2 (pt)	2017-05-23	composto, composição farmacêutica, uso de um composto, e, método para o tratamento ou prevenção de distúrbios neurológicos e psiquiátricos associados com a disfunção de glutamato em um animal.
BRPI0812740A2 (pt)	2016-07-19	composto, composição farmacêutica, uso do composto, e, método para tratamento, prevenção ou alívio de um distúrbio do sistema nervoso central de um corpo de animal vivo.
BRPI0814529A2 (pt)	2015-01-27	Derivados de 2-3-dihidrobenzo[1,4]dioxin-2-ilmetil como antagonistas alfa2c para o uso no tratamento de doenças do sistema nervoso periférico e central.
BRPI0816881A2 (pt)	2015-03-17	Composto, composição farmacêutica, uso de um composto, e, métodos para tratar doenças ou distúrbios e para preparar um composto.
CL2007002974A1 (es)	2008-05-23	Compuestos derivados de benzoimidazol; composicion farmaceutica; y uso para el tratamiento de trastornos asociados con dgat1.
BRPI0909768A2 (pt)	2015-10-06	composto, composição farmacêutica, método para o tratamento ou prevenção de uma doença ou distúrbio mediados pela ativação de b3-adrenoceptor, e, uso de um composto""composto, composição farmacêutica, método para o tratamento ou orevenção de uma doença ou distúrbio mediados pela ativação de b3-adrenoceptor, e, uso de um composto
BRPI0619586A2 (pt)	2018-08-28	método para o tratamento ou prevenção de um distúrbio associado com cd40
CL2007003049A1 (es)	2008-05-16	Compuestos derivados de 2,4-diaminopirimidina; composicion farmaceutica, utiles para tratar trastornos proliferativos.
BRPI1009252A2 (pt)	2016-03-15	composto, pró-droga, composição farmacêutica, métodos para prevenir ou tratar doenças do sistema nervoso central, e mal de alzheimer, e, uso do composto ou de uma pró-droga do mesmo
ECSP10010007A (es)	2010-07-30	Tratamiento con ligandos alpha-7-selectivos
BRPI0913585A2 (pt)	2015-10-27	composto, método para fabricar um composto, composição farmacêutica, uso de um composto, e, método para o tratamento ou prevenção de distúrbios
CL2007003155A1 (es)	2008-05-16	Compuestos derivados de 3,7-diazabiciclo[3.3.0]octano o 3,7-diazabiciclo[3.3.1]nonano, moduladores de receptores nicotinicos neuronales; composicion farmaceutica; y uso en el tratamiento de trastornos del snc.
BRPI0915383A2 (pt)	2015-11-03	composto, métodos para tratar um indíviduo que sofre de um distúrbio neurodegenerativo ou psiquiátrico e para tratar um indivíduo que sofre de um vício em droga, e, composição farmacêutica.
BRPI0717219A2 (pt)	2015-05-26	"composição imunogênica, método para tratar ou prevenir doença, e, uso de uma composição imunogênica."
CR8642A (es)	2008-11-28	Compuestos, composiciones farmaceuticas y metodos para su uso en el tratameinto de desordenes metabolicos
WO2007126957A3 (en)	2008-01-24	New compounds
CL2011000043A1 (es)	2011-10-28	Compuestos derivados de benzoazepina sustituidos; compuestosintermediarios; metodo de sintesis; composicion farmaceutica; y uso en el tratamiento o prevencion de un trastorno del sistema nervioso central.
BRPI0811262A2 (pt)	2014-11-04	Composto, composto ou sal do mesmo, composição farmacêutica, modulador de receptor de glicocorticóide, método para prevenção e/ou tratamento de bistúrbios metabólicos, doenças inflamatórias, doenças auto-imunes, doenças alérgicas, doenças do sistema nervoso central, doenças cardiovasculares, doenças relacionadas com homeostase ou glaucoma, e uso de pelo menos um composto ou um sal do mesmo
BRPI0917705A2 (pt)	2016-02-16	composto, pró-droga, composição farmacêutica, método para tratar ou prevenir uma doença ou condição, e, uso do composto
BRPI0814957A2 (pt)	2015-02-03	Composto, pró-droga, agente farmacêutico, método para a profilaxia ou tratamento de uma doença, distúrbio ou condição, e, uso do composto.
BRPI0815591A2 (pt)	2015-03-03	Composto, composição farmacêutica, uso de um composto, e, método para tratar uma doença, condição ou distúrbio.
BRPI0922452A2 (pt)	2015-12-15	composto, composição farmacêutica, uso em um composto, e método para prevenir, tratar ou melhorar doenças ou condições dérmicas, ou distúrbios de ferimento cutâneo agudos ou crônicos.
BRPI0807749A2 (pt)	2014-06-17	Composto, composição farmacêutica, e, método para a prevenção, tratamento ou melhora de doenças ou condições dérmicas, ou distúrbios de ferida cutânea agudos ou crônicos.
CL2007002578A1 (es)	2008-07-04	Compuestos derivados de n-(1-ftalazin-1-il-piperidin-4-il)-amidas; composicion farmaceutica; y uso para el tratamiento y prevencion de trastornos de la fertilidad, osteoporosis y cancer.
BRPI0818448A2 (pt)	2015-05-12	Composto, composição farmacêutica, uso de um composto, e, métodos para o tratamento ou prevenção de um distúrbio madiano pelo receptor mglur5.

Legal Events

Date	Code	Title
2017-06-06	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
2017-09-19	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]
2021-07-13	B350	Update of information on the portal [chapter 15.35 patent gazette]